Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
MORF Morphic Holding, Inc. daily Stock Chart
MORF [NASD]
Morphic Holding, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.56 Insider Own0.90% Shs Outstand30.53M Perf Week9.98%
Market Cap1.01B Forward P/E- EPS next Y-1.88 Insider Trans-44.82% Shs Float18.31M Perf Month21.88%
Income-47.10M PEG- EPS next Q-0.53 Inst Own61.80% Short Float4.28% Perf Quarter19.12%
Sales38.70M P/S26.19 EPS this Y-78.70% Inst Trans2.55% Short Ratio11.95 Perf Half Y60.32%
Book/sh4.27 P/B7.51 EPS next Y-29.90% ROA- Target Price37.25 Perf Year97.78%
Cash/sh6.74 P/C4.76 EPS next 5Y- ROE- 52W Range9.90 - 34.48 Perf YTD86.95%
Dividend- P/FCF- EPS past 5Y- ROI-34.00% 52W High-6.96% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low224.04% ATR1.74
Employees76 Current Ratio6.10 Sales Q/Q352.60% Oper. Margin- RSI (14)65.93 Volatility6.73% 5.88%
OptionableNo Debt/Eq0.00 EPS Q/Q156.00% Profit Margin- Rel Volume0.63 Prev Close32.57
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume65.49K Price32.08
Recom1.80 SMA2012.41% SMA5016.37% SMA20044.13% Volume41,384 Change-1.50%
Oct-26-20Initiated RBC Capital Mkts Outperform $35
Jul-22-19Initiated Wells Fargo Outperform
Jul-22-19Initiated Jefferies Buy
Jul-22-19Initiated Cowen Outperform
Jul-22-19Initiated BMO Capital Markets Outperform $30
Nov-17-20 09:05AM  
Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference
GlobeNewswire
Nov-11-20 06:50AM  
Results: Morphic Holding, Inc. Confounded Analyst Expectations With A Surprise Profit
Simply Wall St. +6.34%
Nov-09-20 07:00AM  
Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results
GlobeNewswire
Nov-05-20 10:40AM  
We Think Morphic Holding (NASDAQ:MORF) Can Easily Afford To Drive Business Growth
Simply Wall St.
Oct-12-20 07:00AM  
Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020
GlobeNewswire
Sep-28-20 10:01AM  
A Look Into Healthcare Sector Value Stocks
Benzinga
Sep-23-20 06:30AM  
Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
GlobeNewswire -6.59%
Sep-21-20 04:45PM  
Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit
GlobeNewswire -6.58%
Sep-03-20 04:30PM  
Morphic Announces Participation in Upcoming Investor Conferences
GlobeNewswire
Aug-25-20 08:38AM  
The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout
Benzinga
06:30AM  
Morphic Announces that AbbVie Exercises License Option to v6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
GlobeNewswire
Aug-10-20 08:35AM  
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Tops Revenue Estimates
Zacks +9.53%
07:00AM  
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
GlobeNewswire
Aug-07-20 03:34PM  
Morphic Holding's (NASDAQ:MORF) Stock Price Has Reduced13% In The Past Year
Simply Wall St.
Aug-03-20 12:31PM  
Morphic Holding, Inc. (MORF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks
Jun-29-20 07:30AM  
Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020
GlobeNewswire +5.32%
Jun-18-20 08:00AM  
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
GlobeNewswire
Jun-15-20 09:36PM  
Hedge Funds Nibbling On Morphic Holding, Inc. (MORF)
Insider Monkey
May-27-20 08:00AM  
Morphic to Present at the Jefferies Virtual Healthcare Conference
GlobeNewswire
May-06-20 04:05PM  
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
GlobeNewswire
Apr-29-20 04:15PM  
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
GlobeNewswire +9.82%
Apr-07-20 08:00AM  
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
GlobeNewswire -12.47%
Mar-17-20 08:00AM  
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
GlobeNewswire +19.93%
Feb-28-20 08:00AM  
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
GlobeNewswire
Feb-27-20 04:05PM  
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
GlobeNewswire
Feb-14-20 11:29AM  
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the 47 Integrin and Potential Treatment for Inflammatory Bowel Disease
GlobeNewswire -9.77%
Jan-08-20 12:00PM  
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
GlobeNewswire
Nov-30-19 09:40AM  
Hedge Funds Are Dumping Morphic Holding, Inc. (MORF)
Insider Monkey
Nov-18-19 04:15PM  
Morphic to Present at the Jefferies 2019 London Healthcare Conference
GlobeNewswire
Nov-12-19 04:24PM  
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
GlobeNewswire
Oct-30-19 10:35AM  
Hedge Funds Have Never Been This Bullish On Morphic Holding, Inc. (MORF)
Insider Monkey
Aug-30-19 01:00PM  
Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference
GlobeNewswire
Aug-12-19 06:30AM  
Morphic Announces Corporate Highlights and Second Quarter 2019 Financial Results
GlobeNewswire -7.84%
Jul-17-19 09:00AM  
Pandion Therapeutics Appoints Rahul Kakkar, MD, as Chief Executive Officer
Business Wire -5.02%
Jul-01-19 04:30PM  
Morphic Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
Business Wire +17.20%
Jun-26-19 08:30PM  
Morphic Announces Pricing of Upsized Initial Public Offering
Business Wire
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral av6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a47 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR 6 #2, a selective av6 specific integrin inhibitor to treat IPF and PSC; and av1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrodinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics; and drug discovery research collaboration with HitGen Inc. to identify small molecule leads against targets specified by the company. The company was founded in 2014 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tipirneni Praveen P.President and CEONov 18Option Exercise4.323271,4133,813Nov 19 07:00 PM
Tipirneni Praveen P.President and CEONov 18Sale30.0034210,260642,474Nov 19 07:00 PM
Tipirneni Praveen P.President and CEONov 18Sale30.003279,8103,486Nov 19 07:00 PM
DeVaul WilliamGeneral Counsel and SecretaryNov 17Option Exercise4.324,27518,4687,561Nov 19 06:59 PM
Tipirneni Praveen P.President and CEONov 17Option Exercise4.322,71311,7206,199Nov 19 07:00 PM
Tipirneni Praveen P.President and CEONov 17Sale30.102,71781,788642,816Nov 19 07:00 PM
Tipirneni Praveen P.President and CEONov 17Sale30.102,71381,6543,486Nov 19 07:00 PM
DeVaul WilliamGeneral Counsel and SecretaryNov 17Sale30.104,275128,6733,286Nov 19 06:59 PM
DeVaul WilliamGeneral Counsel and SecretaryNov 16Option Exercise4.325002,1603,786Nov 16 07:37 PM
Tipirneni Praveen P.President and CEONov 16Option Exercise4.322008643,486Nov 16 07:38 PM
Tipirneni Praveen P.President and CEONov 16Sale30.052006,009645,533Nov 16 07:38 PM
Tipirneni Praveen P.President and CEONov 16Sale30.0250015,0093,286Nov 16 07:38 PM
DeVaul WilliamGeneral Counsel and SecretaryNov 16Sale30.0550015,0233,286Nov 16 07:37 PM
DeVaul WilliamGeneral Counsel and SecretaryNov 13Option Exercise4.325302,2903,816Nov 16 07:37 PM
Tipirneni Praveen P.President and CEONov 13Option Exercise4.323001,2963,586Nov 16 07:38 PM
Tipirneni Praveen P.President and CEONov 13Sale30.0234110,236645,733Nov 16 07:38 PM
DeVaul WilliamGeneral Counsel and SecretaryNov 13Sale30.0053015,9013,286Nov 16 07:37 PM
DeVaul WilliamGeneral Counsel and SecretaryNov 12Option Exercise4.323901,6853,676Nov 16 07:37 PM
Tipirneni Praveen P.President and CEONov 12Option Exercise4.324601,9873,746Nov 16 07:38 PM
Tipirneni Praveen P.President and CEONov 12Sale30.0040012,000646,074Nov 16 07:38 PM
Tipirneni Praveen P.President and CEONov 12Sale30.0046013,8003,286Nov 16 07:38 PM
DeVaul WilliamGeneral Counsel and SecretaryNov 12Sale30.0039011,7003,286Nov 16 07:37 PM
Lugovskoy AlexeyChief Development OfficerNov 10Sale28.135,315149,53485,248Nov 12 07:10 PM
Farrell Robert E JrSVP Finance and CAONov 10Sale28.125,040141,72747,934Nov 12 07:08 PM
Tipirneni Praveen P.President and CEONov 09Option Exercise4.322,50810,8355,794Nov 09 07:06 PM
Farrell Robert E JrSVP Finance and CAONov 09Sale28.0080022,40052,974Nov 12 07:08 PM
Lugovskoy AlexeyChief Development OfficerNov 09Sale28.0090025,20090,563Nov 12 07:10 PM
Tipirneni Praveen P.President and CEONov 09Sale27.662,59571,765646,474Nov 09 07:06 PM
Tipirneni Praveen P.President and CEONov 09Sale27.612,50869,2373,286Nov 09 07:06 PM
Tipirneni Praveen P.President and CEONov 06Option Exercise4.324,36718,8657,653Nov 09 07:06 PM
Tipirneni Praveen P.President and CEONov 06Sale26.134,331113,157649,069Nov 09 07:06 PM
Tipirneni Praveen P.President and CEONov 06Sale26.144,367114,1453,286Nov 09 07:06 PM
Tipirneni Praveen P.President and CEONov 05Option Exercise4.326,64328,6989,929Nov 09 07:06 PM
Tipirneni Praveen P.President and CEONov 05Sale26.856,525175,210653,400Nov 09 07:06 PM
Tipirneni Praveen P.President and CEONov 05Sale26.856,643178,3493,286Nov 09 07:06 PM
Tipirneni Praveen P.President and CEONov 04Option Exercise4.326,10026,3529,386Nov 04 07:07 PM
Tipirneni Praveen P.President and CEONov 04Sale26.586,238165,789659,925Nov 04 07:07 PM
Tipirneni Praveen P.President and CEONov 04Sale26.586,100162,1283,286Nov 04 07:07 PM
Tipirneni Praveen P.President and CEONov 03Option Exercise4.322,60511,2545,891Nov 04 07:07 PM
Tipirneni Praveen P.President and CEONov 03Sale26.002,57566,945666,163Nov 04 07:07 PM
Tipirneni Praveen P.President and CEONov 03Sale25.992,60567,7143,286Nov 04 07:07 PM
Tipirneni Praveen P.President and CEONov 02Option Exercise4.327,77733,59711,063Nov 04 07:07 PM
Tipirneni Praveen P.President and CEONov 02Sale25.667,736198,470668,738Nov 04 07:07 PM
Tipirneni Praveen P.President and CEONov 02Sale25.647,777199,4013,286Nov 04 07:07 PM
Lugovskoy AlexeyChief Development OfficerOct 26Sale28.331,36738,72691,463Oct 27 07:07 PM
Farrell Robert E JrSVP Finance and CAOOct 26Sale28.231,76049,68053,774Oct 27 07:06 PM
Farrell Robert E JrSVP Finance and CAOOct 23Sale28.312,30065,11055,534Oct 27 07:06 PM
Lugovskoy AlexeyChief Development OfficerOct 23Sale28.312,31865,62492,830Oct 27 07:07 PM
Lugovskoy AlexeyChief Development OfficerOct 19Sale28.221002,82295,148Oct 21 07:09 PM
Farrell Robert E JrSVP Finance and CAOOct 19Sale28.051002,80557,834Oct 21 07:08 PM
Farrell Robert E JrSVP Finance and CAOOct 12Sale27.021,14931,04857,934Oct 13 07:03 PM
Lugovskoy AlexeyChief Development OfficerOct 12Sale27.0371819,40995,248Oct 13 07:05 PM
Lugovskoy AlexeyChief Development OfficerOct 09Sale26.801,00026,80395,966Oct 13 07:05 PM
Farrell Robert E JrSVP Finance and CAOOct 09Sale26.751,91651,26159,083Oct 13 07:03 PM
Lugovskoy AlexeyChief Development OfficerOct 08Sale26.7190524,16896,966Oct 08 07:00 PM
Farrell Robert E JrSVP Finance and CAOOct 08Sale26.711,91551,14960,999Oct 08 06:59 PM
Farrell Robert E JrSVP Finance and CAOOct 07Sale26.086,584171,68662,914Oct 08 06:59 PM
Lugovskoy AlexeyChief Development OfficerOct 07Sale26.063,21383,74197,871Oct 08 07:00 PM
Lugovskoy AlexeyChief Development OfficerOct 06Sale26.4263716,831101,084Oct 08 07:00 PM
Farrell Robert E JrSVP Finance and CAOOct 06Sale26.371,31534,67369,498Oct 08 06:59 PM
Farrell Robert E JrSVP Finance and CAOOct 05Sale26.562,00053,11970,813Oct 05 07:17 PM
Lugovskoy AlexeyChief Development OfficerOct 05Sale26.501,00026,500101,721Oct 05 07:19 PM
Lugovskoy AlexeyChief Development OfficerOct 02Sale26.1190023,502102,721Oct 05 07:19 PM
Farrell Robert E JrSVP Finance and CAOOct 02Sale26.151,84248,16572,813Oct 05 07:17 PM
Farrell Robert E JrSVP Finance and CAOOct 01Sale27.613,27990,53774,655Oct 05 07:17 PM
Lugovskoy AlexeyChief Development OfficerOct 01Sale27.601,62744,897103,621Oct 05 07:19 PM
DeVaul WilliamGeneral Counsel and SecretaryAug 14Option Exercise4.321,2015,1883,701Aug 17 06:44 PM
DeVaul WilliamGeneral Counsel and SecretaryAug 14Sale30.341,20136,4402,500Aug 17 06:44 PM
DeVaul WilliamGeneral Counsel and SecretaryAug 13Option Exercise4.321,1044,7693,604Aug 17 06:44 PM
DeVaul WilliamGeneral Counsel and SecretaryAug 13Sale30.131,10433,2662,500Aug 17 06:44 PM
Lugovskoy AlexeyChief Development OfficerJul 09Sale24.9951312,818105,248Jul 09 07:32 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 08Option Exercise4.328563,6983,356Jul 09 07:31 PM
Lugovskoy AlexeyChief Development OfficerJul 08Sale24.883,63090,303105,761Jul 09 07:32 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 08Sale24.8485621,2632,500Jul 09 07:31 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 07Option Exercise4.321,2615,4483,761Jul 09 07:31 PM
Lugovskoy AlexeyChief Development OfficerJul 07Sale25.855,001129,265109,391Jul 09 07:32 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 07Sale25.951,26132,7182,500Jul 09 07:31 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 06Option Exercise4.322,2009,5044,700Jul 06 07:44 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 06Sale25.882,20056,9342,500Jul 06 07:44 PM
Lugovskoy AlexeyChief Development OfficerJul 06Sale25.874,304111,344114,392Jul 06 08:19 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 02Option Exercise4.325,40023,3287,900Jul 06 07:44 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 02Sale26.515,400143,1332,500Jul 06 07:44 PM
Lugovskoy AlexeyChief Development OfficerJul 02Sale26.4710,039265,734118,696Jul 06 08:19 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 01Option Exercise4.322,2839,8634,783Jul 06 07:44 PM
Lugovskoy AlexeyChief Development OfficerJul 01Sale26.544,513119,790128,735Jul 06 08:19 PM
DeVaul WilliamGeneral Counsel and SecretaryJul 01Sale26.512,28360,5332,500Jul 06 07:44 PM
Rogers BruceChief Scientific OfficerJun 10Sale23.3325,000583,251153,319Jun 12 06:34 PM
Farrell Robert E JrSVP Finance and CAOJun 01Sale20.356,681135,97277,934Jun 01 07:10 PM
Farrell Robert E JrSVP Finance and CAOMay 29Sale20.1713,319268,67284,615Jun 01 07:10 PM
Rogers BruceChief Scientific OfficerMay 28Sale22.5520,000450,914178,319May 29 07:17 PM
open in yahoo | open in reuters | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.